Ordering Recommendation

Monitor patient compliance.


Qualitative Enzyme-Linked Immunosorbent Assay/ Quantitative Gas Chromatography-Mass Spectrometry/Quantitative Liquid Chromatography-Tandem Mass Spectrometry




1-2 days
Confirmation: 1-4 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation

Gray (sodium fluoride/potassium oxalate). Also acceptable: Plain red, green (sodium heparin), lavender (EDTA), or pink (K2EDTA).

Specimen Preparation

Remove plasma from cells ASAP or within 2 hours of collection. Transfer 4 mL plasma to an ARUP Standard Transport Tube. (Min: 3 mL) Also acceptable: Serum.

Storage/Transport Temperature


Unacceptable Conditions

Specimens exposed to repeated freeze/thaw cycles. Separator tubes. Plasma or whole blood collected in lt. blue (sodium citrate).


Cocaine and cocaethylene are more stable in fluoride-preserved plasma than serum.


After separation from cells: Ambient: 1 week; Refrigerated: 2 weeks; Frozen: 3 years

Reference Interval
Drugs Covered and Cutoff Concentrations
Drugs/Drug Classes
Amphetamines 30 ng/mL
Methamphetamine 30 ng/mL
Barbiturates 75 ng/mL
Benzodiazepines 75 ng/mL
Buprenorphine Effective Aug 15, 2016
1 ng/mL
Cannabinoids 30 ng/mL
Cocaine 30 ng/mL
Methadone 40 ng/mL
Opiates 30 ng/mL
Oxycodone 30 ng/mL
Phencyclidine 15 ng/mL

Interpretive Data

Drugs/Drug classes reported as "Positive" are automatically reflexed to mass spectrometry confirmation/quantitation. An unconfirmed positive immunoassay screen result may be useful for medical purposes but does not meet forensic standards. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. Specimens for which drugs or drug classes are detected by the screen are automatically reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

For medical purposes only; not valid for forensic use.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.


Screen-positive specimens are automatically confirmed by GC/MS and/or LC-MS/MS; additional charges may apply.

Hotline History
CPT Codes

80307; if reflexed, add 80324; 80345; 80346; 80348; 80349; 80353; 80358; 80359; 80361; 80365; 83992 (Reflexed Alt Code: G0480 )

Component Test Code* Component Chart Name LOINC
0092419 Drug Screen Comments, Serum or Plasma 48767-8
0092421 Cannabinoids, S/P, Screen 8172-9
0092422 Cocaine, S/P, Screen 8191-9
0092423 Opiates, S/P, Screen 8219-8
0092424 Phencyclidine, S/P, Screen 8236-2
0092425 Amphetamines, S/P, Screen 8149-7
0092426 Barbiturates, S/P, Screen 20421-4
0092427 Benzodiazepines, S/P, Screen 46976-7
0092428 Methadone, S/P, Screen 59705-4
0092430 Oxycodone, S/P, Screen 13576-4
0093414 Methamphetamine, S/P, Screen 3777-0
2013568 Buprenorphine, S/P, Screen 3413-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Pain Management
Drug Screen 9 Panel, Serum or Plasma - Immunoassay Screen with Reflex to Mass Spectrometry Confirmation/Quantitation